TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer

Table 5 Univariate Cox regression analysis for clinicopathological features and genotypes

Variable	HR	DFS 95%CI	P value	HR	OS 95%CI	P value
Age < 65 yr	1.513	0.873-2.621	0.140	1.229	0.682-2.213	0.492
Rectal Ca	1.550	0.890-2.703	0.121	1.282	0.713-2.306	0.406
Stage III vs I%II	2.532	1.368-4.695	0.003	1.877	1.009-3.494	0.047
Grade III and IV vs I and II	1.984	1.143-3.436	0.015	2.097	1.166-3.770	0.013
KRAS mutation	1.330	0.761-2.326	0.321	1.283	0.702-2.346	0.418
BRAF V600E mutation	1.276	0.310-5.255	0.736	2.743	0.845-8.902	0.093
TYMS 5’UTR			0.397			0.766
2R	1			1
2R/3R	1.213	0.498-2.958	0.671	0.745	0.332-1.672	0.475
3R	1.690	0.678-4.213	0.260	0.846	0.355-2.020	0.707
TYMS 5’UTR			0.596			0.615
2RG/3RG	1			1
2RG/2RG	1.038	0.377-2.858	0.942	1.750	0.672-4.559	0.252
2RG/3RC	1.523	0.684-3.394	0.303	1.625	0.702-3.760	0.257
3RC/3RC	1.414	0.482-4.148	0.528	0.680	0.146-3.162	0.623
3RG/3RC	2.128	0.902-5.018	0.085	1.782	0.686-4.625	0.235
3RG/3RG	1.489	0.466-4.672	0.502	1.996	0.610-6.532	0.253
TYMS 5’UTR			0.204			0.589
2RG/3RG	1			1
2RG/2RG	1.702	0.343-8.441	0.515	3.322	0.787-14.03	0.102
2RG/3RC	2.935	0.778-11.08	0.112	3.034	0.803-11.46	0.102
2RG/3RCLOH	5.387	1.427-20.34	0.013	3.879	0.967-15.56	0.056
2RG/3RGLOH	2.138	0.431-10.60	0.352	2.026	0.408-10.06	0.388
2RGLOH/3RC	3.178	0.640-15.78	0.157	3.109	0.626-15.44	0.165
2RGLOH/3RG	7.402	1.648-33.24	0.009	6.127	1.358-27.64	0.018
3RC/3RC	4.326	1.031-18.15	0.045	1.733	0.288-10.42	0.548
3RG/3RC	4.865	1.336-17.72	0.016	3.438	0.888-13.32	0.074
3RG/3RG	3.413	0.761-15.30	0.109	3.994	0.887-17.99	0.071
TYMS 5’UTR groups			0.130			0.223
A1	1.136	0.574-2.251	0.714	1.882	0.917-3.861	0.085
B2	1			1
C3	1.908	0.980-3.713	0.057	1.309	0.637-2.692	0.464
TYMS 3’UTR			0.791			0.846
del/del	1.170	0.496-2.760	0.721	1.145	0.456-2.873	0.773
ins/del	1.244	0.664-2.329	0.495	1.219	0.622-2.387	0.564
ins/ins	1			1
TYMS 3’UTR			0.299			0.391
del/del	0.624	0.244-1.595	0.324	0.634	0.228-1.761	0.382
del/LOH	0.374	0.086-1.630	0.190	0.408	0.093-1.797	0.236
ins/del	0.634	0.329-1.224	0.175	0.743	0.372-1.482	0.399
ins/LOH	1			1
ins/ins	0.417	0.172-1.016	0.054	0.391	0.140-1.087	0.072
ins/ins vs ELSE	0.593	0.267-1.318	0.200	0.511	0.201-1.297	0.158
ins/LOH vs ELSE	1.807	1.000-3.266	0.050	1.650	0.877-3.104	0.120
ins/del vs ELSE	0.976	0.556-1.713	0.933	1.131	0.626-2.044	0.684
del/del vs ELSE	0.964	0.411-2.262	0.934	0.907	0.358-2.299	0.837
del/LOH vs ELSE	0.565	0.137-2.327	0.430	0.570	0.138-2.359	0.438
LOH	1.480	0.833-2.629	0.181	1.350	0.732-2.487	0.336
SNP G->C	1.542	0.878-2.707	0.132	1.108	0.617-1.992	0.731

¹Low expression profile;

²Medium expression profile;

³High expression profile. DFS: Disease-free survival; OS: Overall survival; HR: Hazard ratios; CI: Confidence interval; Ca: Cancer; TYMS: Thymidylate synthase gene; UTR: Untranslated region; LOH: Loss of heterozygosity; 5FU: 5-fluorouracil; SNP: Single nucleotide polymorphism.